SCHEMBL7689353

SCHEMBL7689353

CC(=O)NCC(=O)[C@H](Cc1ccccc1)NC(=O)c1cccc(NS(=O)(=O)c2ccc3ncccc3c2)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
LMNA P02545 2/20 0.44
PFKFB3 Q16875 1/20 0.42
CCR1 P32246 1/20 0.42
HSD17B1 P14061 1/20 0.41
HSD17B2 P37059 1/20 0.41
NAMPT P43490 2/20 0.41
BCAT1 P54687 1/20 0.41
HTT P42858 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
HDAC1 Q13547 2/20 0.40
PABPC1 P11940 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
PHGDH O43175 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7696803 0.94 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAPFKFB3CCR1
SCHEMBL7699311 0.91 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2LMNAPFKFB3CCR1
SCHEMBL7695396 0.89 AKR1C3 (0.48) ALDH1A1SMN1; SMN2LMNAHTTNPSR1
SCHEMBL7694334 0.86 ALDH1A1 (0.49) ALDH1A1PFKFB3MEN1KMT2A
SCHEMBL7689558 0.81 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2LMNAHDAC1MEN1
SCHEMBL7694179 0.80 AKR1C3 (0.48) ALDH1A1SMN1; SMN2LMNA
SCHEMBL7695659 0.79 KDM1A (0.51) ALDH1A1PFKFB3MEN1MAPTKMT2A
SCHEMBL7692550 0.79 AKR1C3 (0.51) ALDH1A1SMN1; SMN2LMNAPFKFB3MEN1
SCHEMBL7658785 0.77 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAHDAC1MEN1
SCHEMBL7695272 0.76 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2LMNAHDAC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436925-B1 BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES ABBOTT LABORATORIES 2002-08-20 US disclosed